Literature DB >> 16138366

Ultrasound-assisted transthoracic biopsy: cells or sections?

Pawel Schubert1, Colleen A Wright, Mercia Louw, Karen Brundyn, Johan Theron, Chris T Bolliger, Andreas H Diacon.   

Abstract

Physicians increasingly use transthoracic ultrasound (US) as an aid for diagnostic procedures. At the bedside, US helps to visualize neoplasms in the chest wall, pleura, peripheral lung, and anterior mediastinum involving or abutting the pleura. Histology specimens from cutting-needle biopsies have been shown to be safe and effective. This prospective study determined the yield and safety of US-guided fine-needle aspiration biopsy (FNAB) as a first-line bedside investigation. We recruited 97 consecutive patients, and of these, 85 underwent both cutting-needle biopsy and FNAB. These were adequate for diagnosis in 81.2% and 80% of cases, respectively, with a combined yield of 90%. Measured with a novel semiquantitative score, FNAB allowed a diagnosis with fewer special investigations than cutting biopsy. US-guided FNAB by pulmonologists performed best in lung carcinoma and can be recommended as a first-line investigation in patients with a high clinical suspicion of this diagnosis. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Year:  2005        PMID: 16138366     DOI: 10.1002/dc.20342

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  3 in total

1.  Interventional ultrasonography of the chest: Techniques and indications.

Authors:  J Almolla; G Balconi
Journal:  J Ultrasound       Date:  2011-02-12

2.  Utility of contrast-enhanced ultrasound with SonoVue in biopsy of small subpleural nodules.

Authors:  Jinlin Wang; Dazhi Zhou; Xiaohong Xie; Panxiao Shen; Yunxiang Zeng
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review.

Authors:  X Yao; M M Gomes; M S Tsao; C J Allen; W Geddie; H Sekhon
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.